Diabetes drug shows promise for fatty liver – new study launches
NCT ID NCT06982378
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This study looks at whether a GLP-1 RA drug (a type of diabetes medication) can improve liver fat and blood fat levels in people with metabolic fatty liver disease (MASLD), type 2 diabetes, and obesity. About 30 adults already taking a stable dose of GLP-1 RA will have a liver biopsy and blood tests to measure changes in fats and related genes. The goal is to understand how this drug affects liver and body fat at a molecular level.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert Hospital
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.